Ixekizumab
- Generic Name
- Ixekizumab
- Brand Names
- Taltz
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1143503-69-8
- Unique Ingredient Identifier
- BTY153760O
- Background
Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflammatory conditions. In particular, IL-17A h...
- Indication
Ixekizumab is indicated for the treatment of patients aged six years or older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. It is also indicated in adult patients with active psoriatic arthritis, ankylosing spondylitis, or non-radiographic axial spondyloarthritis with objective signs of inflammation.
- Associated Conditions
- Moderate to Severe Plaque Psoriasis, Active Ankylosing spondylitis, Active Non-radiographic Axial Spondyloarthritis, Active Psoriatic arthritis
- Associated Therapies
- -
Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2017-03-08
- Last Posted Date
- 2021-09-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 201
- Registration Number
- NCT03073200
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸Modern Research Associates PLLC, Dallas, Texas, United States
🇲🇽Hospital Univ. Dr. Jose Eleuterio Gonzalez, Monterrey, Nuevo León, Mexico
A Study of Ixekizumab in Participants With Plaque Psoriasis
- First Posted Date
- 2016-12-15
- Last Posted Date
- 2019-03-12
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 28
- Registration Number
- NCT02993471
- Locations
- 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
🇺🇸Avail Clinical Research LLC, DeLand, Florida, United States
🇺🇸High Point Clinical Trials Center, High Point, North Carolina, United States
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
- First Posted Date
- 2016-05-02
- Last Posted Date
- 2020-03-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 303
- Registration Number
- NCT02757352
- Locations
- 🇺🇸
Institute of Arthritis Research, Idaho Falls, Idaho, United States
🇺🇸TriWest Research Assocaites, El Cajon, California, United States
🇺🇸Desert Medical Advances, Palm Desert, California, United States
A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis
- First Posted Date
- 2016-03-24
- Last Posted Date
- 2019-09-16
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 149
- Registration Number
- NCT02718898
- Locations
- 🇺🇸
Modern Research Associates PLLC, Dallas, Texas, United States
🇺🇸Menter Dermatology Research Institute, Dallas, Texas, United States
🇺🇸Tufts Medical Center, Boston, Massachusetts, United States
A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis
- Conditions
- Interventions
- First Posted Date
- 2016-03-02
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 341
- Registration Number
- NCT02696785
- Locations
- 🇺🇸
Klein and Associates MD, PA, Hagerstown, Maryland, United States
🇺🇸Marietta Rheumatology, Marietta, Georgia, United States
🇺🇸Sarasota Arthritis Center, Sarasota, Florida, United States
A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis
- First Posted Date
- 2016-03-02
- Last Posted Date
- 2020-06-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 316
- Registration Number
- NCT02696798
- Locations
- 🇺🇸
Rheumatology Center of San Diego, Escondido, California, United States
🇺🇸Care Access Research - Huntington Beach, Huntington Beach, California, United States
🇺🇸Arthritis Assoc. & Osteoporosis Ctr of Colorado Springs, LLC, Colorado Springs, Colorado, United States
A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis Naive to Systemic Treatment
- Conditions
- Interventions
- First Posted Date
- 2015-12-18
- Last Posted Date
- 2019-10-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 162
- Registration Number
- NCT02634801
- Locations
- 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ulm, Germany
🇩🇪For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Kiel, Germany
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
- First Posted Date
- 2015-10-23
- Last Posted Date
- 2019-11-15
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 394
- Registration Number
- NCT02584855
- Locations
- 🇺🇸
Heartland Research Associates, Wichita, Kansas, United States
🇺🇸University of California, Davis - Health Systems, Sacramento, California, United States
🇺🇸Robert A. Harrell, III, MD, Durham, North Carolina, United States
A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2015-09-28
- Last Posted Date
- 2020-06-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 302
- Registration Number
- NCT02561806
- Locations
- 🇨🇦
For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Toronto, Canada
🇬🇧For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salford, United Kingdom
A Study of the Immune Response to Vaccines and Ixekizumab (LY2439821) in Healthy Participants
- First Posted Date
- 2015-09-07
- Last Posted Date
- 2017-01-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 84
- Registration Number
- NCT02543918
- Locations
- 🇺🇸
Covance, Dallas, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.